Too much, too little, or just right: Tailoring postrevascularization antithrombotic therapy in PAD versus CAD when one size does not fit all

2026/03/19 by Francisco Ujueta, Eric A. Secemsky, Eric A Secemsky · 1 voice · 1 citation
Medicine · #Acute Ischemic Stroke Management #Antiplatelet Therapy and Cardiovascular Diseases #Coronary Interventions and Diagnostics

paper · doi:10.1177/1358863x261426386

crossref issued 2026/03/19 · crossref published 2026/03/19 · crossref published-online 2026/03/19 · openalex publication_date 2026/03/19 · crossref created 2026/03/19 · openalex created_date 2026/03/20 · crossref published-print 2026/04/01 · crossref deposited 2026/05/02 · crossref indexed 2026/05/04 · openalex updated_date 2026/07/22

Cited by

• Comparison of bleeding complications between patients with peripheral and coronary artery disease after revascularization: Insights from ASPARAGUS, a prospective observational study

Discussions

• In follow up to yesterday's post, do not miss commentary by Ujueta and Secemsky on the importance of differences in PAD and CAD—emphasizing higher ischemic and bleeding risks, greater heterogeneity, a [bsky, 0 points, 0 comments]